INTRODUCTION
Access to orphan drugs is often inconsistent, and is hindered by difficulties in demonstrating value in HTA appraisals due to the small patient populations and insufficient data.
AIM
To inform future submissions, we examined the trends and key decision drivers that resulted in a submission being rejected across five HTA agencies.
RESULTS
A total of 29 drugs were licensed for the treatment of 8 rare diseases. PBAC and SMC had the lowest rejection rates, while NICE had the highest (Figure 1 ). 
METHODS
Orphanet database (www.orpha.net) was searched for orphan drugs with a marketing authorization between 2002 and July 2014. Rare diseases for which two or more orphan drugs were available were selected. Decisions from five HTA agencies were considered: AWMSG (Wales), CADTH (Canada), NICE (England), PBAC (Australia), and SMC (Scotland). Assessments that resulted in a rejection were examined for key decision drivers, and for trends and variation by disease type.
CONCLUSIONS
• The proportion of rejected submissions varied by HTA agency, particularly within the HTA bodies in the UK, highlighting inconsistencies in decision-making. Uncertainties in economic evidence and lack of cost-effectiveness were key decision drivers that led to a submission being rejected across all HTA agencies
• An association between prevalence rate and the proportion of rejected submissions was found, with lower rates of disease prevalence correlating with higher acceptance rates. This is most likely due to the lower budget impact incurred in smaller patient populations 
